Chromosome 3p25.3 Gain Is Associated With Cisplatin Resistance and Is an Independent Predictor of Poor Outcome in Male Malignant Germ Cell Tumors.
Dennis M TimmermanThomas F EleveldSruthi SriramLambert C J DorssersAd J M GillisSilvia SchmidtovaKatarina KalavskaHarmen J G van de WerkenChristoph OingFriedemann HoneckerMichal MegoLeendert H J LooijengaPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
On the basis of both in vitro analyses and clinical data, we found 3p25.3 to be strongly associated with cisplatin resistance and poor clinical outcome in male type II GCTs. Using genomic profiling, 3p25.3 status could help to improve risk stratification in male patients with type II GCT. Further characterization of this locus and underlying mechanisms of resistance is warranted to guide development of novel treatment approaches for cisplatin-resistant disease.